Development of a CSFV Erns IgG AlphaLISA® assay capable of differentiating infected from CSFV-vaccinated animals (DIVA)
February 25, 2022
Study aimed to develop a CSFV Erns IgG AlphaLISA® for serum and oral fluids that would complement currently available CSFV E2 DIVA vaccines.